-
Courses
Courses
Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
-
University Life
University Life
Each year more than 4,000 choose University of Galway as their University of choice. Find out what life at University of Galway is all about here.
-
About University of Galway
About University of Galway
Since 1845, University of Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
-
Colleges & Schools
Colleges & Schools
University of Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
-
Research & Innovation
Research & Innovation
University of Galway’s vibrant research community take on some of the most pressing challenges of our times.
-
Business & Industry
Guiding Breakthrough Research at University of Galway
We explore and facilitate commercial opportunities for the research community at University of Galway, as well as facilitating industry partnership.
-
Alumni & Friends
Alumni & Friends
There are 128,000 University of Galway alumni worldwide. Stay connected to your alumni community! Join our social networks and update your details online.
-
Community Engagement
Community Engagement
At University of Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
March NUI Galway joins forces with European network for Covid-19 vaccination trials
NUI Galway joins forces with European network for Covid-19 vaccination trials
NUI Galway has joined forces with a new European network to accelerate clinical trials of Covid-19 vaccines.
The EU VACCELERATE project connects all stakeholders involved in vaccine development on the continent in order to speed up the next two phases of vaccine trials for Covid-19.
Some 21 countries are involved as part of pandemic preparedness on a pan-European scale, creating the backbone of a new structure to coordinate the fast and effective testing of vaccine candidates.
NUI Galway lead, Professor Declan Devane, Deputy Dean of the University’s College of Medicine, Nursing and Health Sciences, said: “We are delighted to play our role in enhancing Ireland’s capacity to conduct vaccine clinical trials for coronavirus and beyond.
“Our role in VACCELERATE focuses on two particular areas - a living mapping and living systematic review of global Covid-19 vaccine trials of which there are currently 164, including 104 which are recruiting participants, and secondly an exploration of the barriers and facilitators to vaccination uptake in adults internationally.”
The VACCELERATE project is led by the University Hospital Cologne, Germany and involves 26 partners from 16 EU-member states and 5 EU-associated countries, with other countries encouraged to join.
NUI Galway and UCD are the Irish partners in the network, with funding provided under EU Horizon 2020.
VACCELERATE will coordinate phase 2 & 3 Covid-19 vaccine trials in all EU-member states and EU-associated countries under one strategic-scientific umbrella.
The network will link capable clinical trial sites, expert knowledge and promote transparent exchange of expertise in the vaccine development field.
An important step in building this network is identifying clinical trial sites, 200 of which have already been identified, and laboratories with the capacity to perform vaccine clinical trials.
VACCELERATE will also facilitate access to vaccine trial volunteers by setting up volunteer registries at https://www.vaccelerate.eu/volunteer-registry/index.html
The project will promote harmonised acquisition, open exchange and consolidation of data for enhanced analysis across trials. This cooperation will generate solutions for characteristic problems in vaccine development that emerge in a pandemic and find answers to identified pressing public health questions.
The European Commission is aiming to use VACCELERATE for the long-term increase of vaccine development capacities.
Ends